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Abstract
New sources of funding have revitalized efforts to control malaria. An effective vaccine would be
a tremendous asset in the fight against this devastating disease and increasing financial and scientific
resources are being invested to develop one. A few candidates have been tested in Phase I and II
clinical trials, and several others are poised to begin trials soon. Some studies have been promising,
and others disappointing.
It is difficult to compare the results of these clinical trials; even independent trials of the same
vaccine give highly discrepant results. One major obstacle in evaluating malaria vaccines is the
difficulty of diagnosing clinical malaria. This analysis evaluates the impact of diagnostic error,
particularly that introduced by microscopy, on the outcome of efficacy trials of malaria vaccines and
make recommendations for improving future trials.
Background
Vaccines which protect against infectious diseases have
saved many lives in the past 200 years, have allowed the
eradication of smallpox and near-eradication of polio,
and are widely regarded as extremely cost-effective inter-
ventions. Vaccines against many common diseases, such
as measles and pertussis, have become part of routine pae-
diatric care and public health programs worldwide.
Malaria is estimated to be the deadliest paediatric disease:
hundreds of thousands of children under five succumb to
malaria each year. An effective vaccine would be a major
advance in public health and is actively being sought. Sev-
eral candidates have been tested in clinical trials and
many more are in various stages of development. Many
aspects of vaccine trial design are important in ensuring
reliable outcomes, but among the most critical are the
choice of primary endpoint and thereby the definition of
vaccine efficacy. In practice, clinical endpoints depend on
three equally important components of malaria diagnosis
– detection, quantification and case definition. The factors
which contribute to accuracy in each component, specifi-
cally with respect to microscopic diagnosis, and their
impact on the calculation of vaccine efficacy for various
types of Phase II and III clinical trial endpoints are exam-
ined.
Measuring vaccine efficacy
Malaria vaccine strategies can be categorized by the stage
of the parasite life cycle which they target. The target of the
vaccine candidate will determine the endpoint that is used
to evaluate its efficacy (Table 1 and Additional File 1).
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Unlike most anti-viral or anti-bacterial vaccines, which
induce complete protection from clinical disease in a high
percentage of vaccinated individuals, no current malaria
vaccine candidates induce complete protection against
infection or clinical malaria. This is consistent with natu-
ral immunity to malaria which does not completely pro-
tect from infection even into adulthood. Malaria vaccine
efficacy (VE) will reflect considerable underlying hetero-
geneity in individual protection and immune response to
the vaccine. With most infectious diseases, VE compares
the frequency of a specified event in the vaccinated popu-
lation to that in the unvaccinated population; in each
individual the event either does or does not occur[1].
With malaria, VE is likely to reflect a relative frequency of
the specified event within an individual as well as within
the population; infections and symptoms will continue to
occur in those successfully vaccinated, albeit less often
and/or with less severity.
Vaccine efficacy is calculated as a ratio, which leads to the
common misconception that uncertainty (i.e. false posi-
tives or false negatives) in the numerator and uncertainty
in the denominator will cancel or balance. This is not the
case, particularly when sensitivity and specificity may dif-
fer in the vaccinated and the control groups. The 95% con-
fidence intervals with which VE is typically reported give
the range of values within which one can be 95% certain
that the true VE lies, based on the observations, but they
reflect only one type of uncertainty. They describe the role
of random chance in the observations and depend on the
sample size and number of observed disease events. They
do not reflect measurement error or other types of uncer-
tainty that may be introduced during the trial. The effect
of the uncertainty of the measurement technique on the
reliability of VE calculations has not been fully evaluated
and must be properly incorporated.
Detecting malaria
When making measurements with categorical conclu-
sions, such as the presence or absence of parasites, meas-
urement uncertainty can decrease the sensitivity and
specificity of the endpoint. Low sensitivity results in a mis-
classification of true positives as negatives and may arise
as a result of measurement error or a case definition that
is too stringent. If the ex ante sensitivity is low, it can be
counterbalanced by increasing the sample size. However,
if the ex post sensitivity (as evaluated after the interven-
tion) is lower in the vaccinated group than in the control
group, a systematic bias is introduced and the VE will be
overestimated[2].
Table 1: Comparison of endpoints of vaccine trials. The mode of action of the vaccine will determine the type of trial and endpoint that 
is used to evaluate their efficacy.
Target of vaccine* Trial Endpoint Vaccine efficacy Type of follow up References
Pre-erythrocytic Sporozoite challenge 
Phase IIa) Infection Daily ACD [30, 31]
Delayed patency (if vaccinees 
become infected) -- Daily ACD [32–34]
Number of primary 
merozoites** Daily ACD [5]
Field trial in endemic setting 
(Phase IIb/III)
Time to first infection or first 
episode 1-HR
ACD (for time to infection) 
ACD or PCD (for first 
episodes)
[35, 36]
Incidence of disease episodes ACD or PCD For multiple
episodes [36]
Blood stage Field trial in endemic setting
Incidence of disease episodes 
(first episode or multiple 
episodes) (Phase IIb/III)
ACD or PCD [15, 16, 37]
Density of infection
(Phase IIb) ACD [9]
N = number of volunteers infected, P = mean number of primary merozoites, HR = Hazards ratio, I=incidence, D = mean density, V = vaccinated, 
UV = unvaccinated, ACD = active case detection, PCD = passive case detection
* Transmission blocking (mosquito stage) vaccines are not considered in this analysis.
** This endpoint requires PCR and is not currently used as a primary endpoint
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False positives may be generated by measurement error or
a case definition that is too inclusive. Specificity less than
100% can have a dramatic impact on the ability to accu-
rately measure VE[3] (Figure 1). For example, a decrease
of 5% in specificity, from 95% to 90%, can reduce the esti-
mated VE by 50% for an attack rate of 5% in the control
group. The impact of specificity on VE becomes important
when the number of false positives becomes a significant
proportion of the total observed positives and increases as
the attack rate declines. In addition, decreased specificity
biases the relative risk in the intervention group towards
1.0, which obscures the difference between vaccine candi-
dates[2]. This will become especially relevant when the
first malaria vaccine is licensed, after which placebo-con-
trolled trials will likely be impossible and Phase IIb and III
trials will be designed to compare between two vaccines.
Classification of an individual as parasite-negative or -
positive by microscopy is not a true binary measurement.
A parasite-negative slide is one which has a parasite den-
sity below the sensitivity, or limit of detection (sensitivity)
of microscopy. The LOD is operator-dependent, but is
also correlated with parasite density and has been shown
to be highly variable at low densities (Figure 2) [4]. This
points to the difficulty of dealing with a source of uncer-
tainty that scales directly with the success of the interven-
tion: if vaccination reduces the parasite density, then the
sensitivity will be lower in the vaccinated cohort.
Variable sensitivity at low parasite densities complicates
the interpretation of Phase IIa challenge studies for pre-
erythrocytic vaccines (Figure 3). Vaccinated and unvacci-
nated individuals are bitten by a predetermined number
of infected mosquitoes. Blood smears are taken at least
once per day to detect the first appearance of parasites. A
delay in the appearance of parasites in the vaccinated
group, relative to the unvaccinated group, is interpreted as
a reduction in the number of surviving pre-erythrocytic
parasites[5]. Figure 3 plots parasite density as a function
of time, assuming simple exponential growth kinetics of
the blood-stage infection, for 30,000 and 3,000 primary
merozoites released from the liver. The curves are always
parallel. Therefore, if the LOD is constant, the delay in
detection of parasites in the vaccinated individual will be
independent of the LOD. However, if the LOD is variable,
then one microscopist may see zero parasites at time (t) in
either sample, but a second microscopist, with a lower
LOD, may see parasites in both vaccinated and unvacci-
nated individuals at time (t+Δt), leading to the erroneous
conclusion that there was no delay in the appearance of
parasites and the vaccine had no effect. For an LOD
between 10 and 100/μl, the windows of detection for a
10-fold and 100-fold reduction in primary merozoites
overlap (Figure 3), potentially reducing the observed VE.
Low sensitivity can have a similar effect on Phase IIb trials
which measure time to first infection in naturally exposed
populations; high rates of false negatives and variable sen-
sitivity can obscure a difference between the vaccinated
and unvaccinated groups. False negatives have less serious
consequences for trial interpretation when the time to first
clinical episodes is measured by passive case detection. If
no parasites are detected at first presentation and patients
are not treated for malaria, then presumably symptoms
The sensitivity of microscopy as a function of parasite density Figure 2
The sensitivity of microscopy as a function of parasite den-
sity. The percentage of microscopists (n = 25) reporting a 
false negative slide versus the mean parasite density reported 
by the remaining microscopists (adapted from [38]).
Estimated vaccine efficacy as a function of sensitivity and spe- cificity for a vaccine with a true efficacy of 80% and an attack  rate of 5% Figure 1
Estimated vaccine efficacy as a function of sensitivity and spe-
cificity for a vaccine with a true efficacy of 80% and an attack 
rate of 5%. Adapted from [3].Malaria Journal 2007, 6:36 http://www.malariajournal.com/content/6/1/36
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Variable sensitivity can obscure differences between vaccinated and unvaccinated individuals in challenge studies Figure 3
Variable sensitivity can obscure differences between vaccinated and unvaccinated individuals in challenge studies. If blood 
smears are read by two different microscopists at time = t1 and time = t2, differences in sensitivity could result in no difference 
seen between the two study subjects. Microscopist A with an LOD of 50 p/μl would read negative smears at time t1. Micro-
scopist B with an LOD of 10 p/μl would read positive smears at time t2. An initial number of merozoites are released from the 
liver at time t = 0 and assumed to grow exponentially with 16 merozoites produced from a single merozoite every 48 hours. 
The table inset gives the "window of detection" of blood-stage infection when the sensitivity varies between 10 and 100 para-
sites per microliter for different numbers of primary merozoites released from the liver.Malaria Journal 2007, 6:36 http://www.malariajournal.com/content/6/1/36
Page 5 of 10
(page number not for citation purposes)
will persist until parasites are detected and the case is
counted.
The specificity of malaria microscopy is also less than per-
fect, and rates of false positives can reach 24% [6]. The
impact of false positives on malaria chemoprophylaxis tri-
als has been evaluated[7]. The analysis is applicable for
clinical trials of pre-erythrocytic vaccines where smears are
prepared regularly to detect infection; even a 1% decrease
in specificity can reduce the observed protective efficacy
by 30%.
Quantifying malaria
Quantifying malaria by microscopy is a difficult task[8],
but the importance of this well-known fact is often over-
looked. Accurate density determination is critical for at
least two endpoints used in clinical trials of malaria vac-
cines. Blood-stage vaccines can be evaluated by the reduc-
tion in density of the blood-stage infection in the
vaccinated versus the control group (Phase IIb)[9], and
clinical episodes of malaria for any type of vaccine are
often defined by a specific density threshold (Phase IIb,
III; see next section). Uncertainty in density determina-
tion may reduce both the sensitivity and specificity of
these endpoints, and the magnitude of the uncertainty is
inversely proportional to the density. When density is
altered by the intervention (vaccination), the result is a
different magnitude of error in the vaccinated versus the
control group.
In a study conducted in Peru and Thailand, thousands of
blood smears were read independently by two micro-
scopists following very detailed protocols[10,11]. The dis-
agreement between the microscopists increased with
decreasing density (Figure 4). At very low densities, the
median difference was greater than 60%. This relationship
between density and discrepancy can be fit with a loga-
rithmic model which describes uncertainty as a continu-
ous function of density. The model can then be used to
incorporate the uncertainty associated with each density
measurement into the calculation of VE. The difference
between the reports from two microscopists reflects the
precision in measuring density but does not give any
information about accuracy per se and is, therefore, not a
measure of distance from true density, but rather of dis-
tance between two measurements.
When comparing parasite densities in the vaccinated and
the control group, uncertainty arising from quantification
of the parasite density can be introduced directly into the
calculation of VE. Figure 5 shows the results of this simu-
lation. As VE increases, the mean density in the numerator
(vaccinated group) decreases and the associated uncer-
tainty increases. Therefore, the percent uncertainty
increases as VE increases. However, the magnitude of the
uncertainty decreases as the sample size increases. If VE is
greater than 80%, an uncertainty of 3% (in the case of 100
individuals in each group) is unlikely to be of serious con-
cern. At intermediate efficacies (40–50%), a 3–4% uncer-
tainty could obscure the difference between successive
iterations of a vaccine over the course of its development,
leading to unwarranted rejection or pursuit of a vaccine
candidate.
Factors other than measurement error can contribute to
uncertainty in parasite density measurements. For exam-
ple, parasite density is reported as parasites per microliter
of blood, but because parasites are counted using white
blood cells (WBCs) as an index, a conversion factor -gen-
erally a uniform approximation of 8,000 WBCs/μl[12]- is
used to convert the number of parasites per WBC into par-
asites per microliter. However, WBC counts may vary with
age, infection status and other factors. Counts can be >
13,000 WBC/μl in asymptomatically infected infants and
as low as 5,400 WBC/μl in asymptomatically infected
adults[13]. WBC counts in malaria-infected, febrile adults
are significantly lower than in uninfected, febrile
adults[14]. Thus, adopting a single, uniform approxima-
tion as a conversion factor can obscure the true parasite
density and potentially lead to even larger errors than the
pure counting errors described above- e.g. over-estimating
Discrepancy in density between two microscopists reading a  single slide as a function of parasite density Figure 4
Discrepancy in density between two microscopists reading a 
single slide as a function of parasite density. Adapted from 
[8]. Parasite density measurements less than 10,000/μl were 
assumed to have an error described by the equation: Error = 
0.61 – 0.054*Ln(Density). Densities greater than or equal to 
10,000/μl were assigned an error of 10%.Malaria Journal 2007, 6:36 http://www.malariajournal.com/content/6/1/36
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parasite densities by 30% relative to true WBC counts[14].
Using complete blood counts to determine the per-patient
WBC count or counting by volume, as has been done in
some studies (i.e. [9,15-17]), can reduce the problem of
patient-to-patient variation in WBC counts.
Temporal fluctuations in parasite density in peripheral
blood are common and may have greater consequences
for parasite density measurement than uncertainty associ-
ated with microscopic quantification. Peaks and troughs
of density may arise from sequestration, or immune
response and the rise of new antigenic variants. Thus it is
seldom clear how to interpret a single measurement of
parasite density in an individual. For example, infections
quantified 24–48 hours apart in each of 11 patients prior
to drug treatment showed an average increase of 5,500
parasites per microliter, with a range of -17,000 to
46,000[18]. A longitudinal study of adults in highly
endemic areas reported frequent fluctuations of 100-fold
in parasite density within as few as 6 hours[19]. Similar
results were seen in children monitored daily[20]. More
studies are necessary to determine whether a single den-
sity determination is an appropriate measurement end-
point for clinical trials.
It is worth noting that body temperature can also fluctuate
on the timescale of hours. Choosing a temperature thresh-
old to define a febrile malaria episode raises similar issues
to choosing a single density threshold.
Defining malaria
In malaria-endemic areas with moderate to high transmis-
sion, the presence of parasites alone or parasites with fever
are not adequate indicators of a clinical malaria episode.
It is not possible to definitively diagnose clinical malaria;
therefore, criteria must be chosen for which a patient will
be considered to be experiencing a clinical malaria epi-
sode. The uncertainty in definition will lead to misclassi-
fication of cases, both false positives and false negatives,
resulting in decreased sensitivity and specificity.
The fraction of parasitaemic, symptomatic individuals
whose malaise is caused by parasites is referred to as the
attributable fraction. The attributable fraction can be cal-
culated by comparing the proportion of febrile individu-
als over a range of parasite densities. Most commonly, a
logistic regression model is fit to the data[21] to describe
the probability that a fever can be attributed to malaria at
any density. The overall attributable fraction is calculated
by averaging this probability over all cases. The logistic
regression model can be used to calculate the sensitivity
and specificity of a particular cut-off density by estimating
the number of true cases that will not be counted because
parasite density falls below the threshold (false negatives)
and the number of non-malaria febrile cases that will be
counted as positive because the density exceeds the
threshold (false positives). Cases of malaria are then
defined by a particular cut-off density which gives the
required sensitivity and specificity. As parasite density
decreases, the probability that symptoms are due to the
observed parasitemia decreases. Therefore, the specificity
of the case definition decreases with decreasing threshold
density, and the observed vaccine efficacy should also
decrease.
The logistic regression model for determining attributable
fraction has been used to determine the sensitivity and
specificity of case definitions in numerous epidemiologi-
cal settings. The cut-off density which gives a case defini-
tion with sufficiently high sensitivity and specificity
depends on many interrelated variables. The appropriate
Percent error associated with vaccine efficacy increases as  vaccine efficacy increases Figure 5
Percent error associated with vaccine efficacy increases as 
vaccine efficacy increases. Plot shows results for 100 and 
1,000 individuals per arm.
 is the mean density in the vaccinated group and   is 
the mean density in the unvaccinated group. The frequency 
of densities in a cohort is described by a gamma distribution 
with a mean density of 3,000 parasites per microliter in the 
unvaccinated group and 1,500 parasites per microliter in the 
vaccinated group. Error associated with each density meas-
urement is calculated using the error model in Figure 4 and 
propagated in the calculation of vaccine efficacy using stand-
ard error propagation methods.
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case definition changes as a function of transmission
intensity[22], and, therefore, season [23]. Age, which
together with transmission intensity determines previous
exposure and immunity, has been correlated to changes in
attributable fraction [13, 22, 23, 24], and sensitivity and
specificity of a particular case definition. Vaccination is
designed to alter the immune status, therefore, the case
definition will necessarily have different sensitivities and
specificities in the vaccinated compared to the unvacci-
nated group. All of these factors complicate comparisons
between trials that use density cut-off case definitions.
Once a threshold density has been chosen to define a clin-
ical episode of malaria, the effect of measurement uncer-
tainty inherent in detecting and quantifying the infection
can be evaluated. Using the density error model, the frac-
tion of cases which are at risk of being mis-categorized
based on the cut-off value can be calculated (Figure 6).
The discrepancy between microscopists is assumed to be
symmetric around the true density, which is a conserva-
tive assumption. These cases could be either mistakenly
included or excluded, so the highest and lowest vaccine
efficacy that can be expected is calculated for a range of
threshold choices. Figure 7 shows the VE that would be
measured with no errors as well as the maximum and
minimum VE that may be observed as determined by the
measurement uncertainty around the threshold density.
The upper and lower bounds are theoretical limits, for
which all the cases that lie within a certain distance of the
threshold are over-counted in one group and under-
counted in the other. It is a highly improbable scenario
when error is randomly distributed, but biased error, such
as an individual microscopist consistently reading higher
or lower than others, could shift the density curve in a sys-
tematic way. As expected, the VE increases with increasing
threshold density and, therefore, increasing specificity of
the case definition. In this particular example, for a case
definition of fever and > 3,000 p/ml, the VE without
measurement error would be 50%, but, based only on the
uncertainty associated with accurately measuring parasite
density, a VE between 40% and 60% may be observed.
These results highlight the risk that a promising vaccine
candidate will be unduly abandoned.
Hypothetical density distribution of clinical episodes of malaria Figure 6
Hypothetical density distribution of clinical episodes of malaria. The distribution of parasite densities among febrile cases is 
approximated by a gamma distribution with a mean of 3,000/μl in the unvaccinated group and vaccination reduces both the 
incidence of fever (25% reduction) and the mean parasite density (30% reduction) among the cohort. A cut-off value of 3,000 
parasites per microliter is shown and the shaded area represents the cases which risk being misclassified due to the discrep-
ancy between microscopists.
MISCLASSIFICATION?
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How to reduce uncertainty?
Understanding the sources and impact of uncertainty can
lead to more robust endpoint definitions in malaria vac-
cine trials. The sensitivity and specificity of microscopy are
highly reader-dependent. However, particularly in the
case of sensitivity, there are intrinsic limitations to micro-
scopy that cannot be completely resolved by improving
reader performance. The shape of the density-error rela-
tionship amongst the study microscopists should be
determined before the study begins. "Over-reading" para-
digms, for example having two microscopists read every
slide and a third microscopist re-read slides with highly
discrepant results, increase the sensitivity and specificity
of microscopy and allow on-going, 'real-time' evaluation
of the density-error relationship.
Density-ratio endpoints seem to be less sensitive to uncer-
tainty than threshold-dependent endpoints, particularly
when the majority of cases fall close to the threshold
value. To reduce the error of a threshold-dependent end-
point, a cut-off value based on the parasite:leukocyte ratio
rather than an absolute density may be used. Evidence
indicates that the parasite:leukocyte ratio is bimodal [13,
25], giving a natural choice for a cut-off value. Deviations
from this cutoff value due to experimental error would
result in fewer misclassified cases. This observation is con-
sistent with data from other studies which showed that
WBC counts were lower in symptomatic, infected individ-
uals compared to those with similar symptoms but no
parasites [14, 26].
Another alternative is to use attributable fraction esti-
mates, arrived at by logistic regression[22, 27, 28] or other
methods [29], to evaluate efficacy. A reduction in the
febrile episodes attributable to malaria across all densities
would be a more accurate indicator of vaccine efficacy
than defining a clinical episode by a cut-off threshold and
would partially eliminate the problem of differing sensi-
tivities and specificities in each arm of the trial. Because
vaccination is intended to alter immune status, the rela-
tionship between density and probability of fever must be
determined by a cross-sectional survey or continuous
active detection in the vaccinated and unvaccinated
cohorts separately. Each febrile episode recorded during
the trial is assigned a probability of being a malaria epi-
sode, as a function of its density using the logistic regres-
sion model [28]. The number of febrile cases attributable
to malaria in the vaccinated and unvaccinated cohorts is
calculated by summing the relative risk for febrile epi-
sodes in each cohort and multiplying by the total number
of febrile cases. This definition of vaccine efficacy reflects
Table 2: Errors in density measurement have little impact on vaccine efficacy calculated by attributable fraction.
Mode of action of vaccine True VE Lower limit Upper limit
30% reduction in density 25% reduction in febrile episodes 39.8 39.3 40.3
50% reduction in density 50% reduction in febrile episodes 89.5 89.5 89.5
70% reduction in density 25% reduction in febrile episodes 89.4 88.9 89.8
, where AF is the attributable fraction, N is the total number of febrile episodes and V and UV designate vaccinated 
and unvaccinated groups, respectively. The vaccine efficacy in the absence of measurement error and the upper and lower bounds that may be 
observed due to measurement error are reported for different levels of reduction in parasite density and number of febrile episodes. The data from 
Smith et al [21] are used to fit the logistic regression model of the probability of fever as a function of parasite density. Density data is simulated by 
randomly choosing cases from specific density categories using a very large data set of febrile patients in order to match the proportions of the 
above data set.
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The observed vaccine efficacy (solid line) and the upper (red  dashed line) and lower (blue dashed line) limit of possible  outcomes as a function of threshold density based on the  uncertainty associated with measurement of parasite density Figure 7
The observed vaccine efficacy (solid line) and the upper (red 
dashed line) and lower (blue dashed line) limit of possible 
outcomes as a function of threshold density based on the 
uncertainty associated with measurement of parasite density. 
Frequency of cases by density is assumed to follow the distri-
bution in Figure 6. The upper and lower bounds are calcu-
lated using the error model in Figure 4.Malaria Journal 2007, 6:36 http://www.malariajournal.com/content/6/1/36
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both the reduction in parasite density and the reduction
in the total number of febrile episodes. It allows for
changes in the relationship between parasitemia and clin-
ical illness. Although density measurement is required,
this technique is less sensitive to error in individual den-
sity measurements because the logistic regression model
represents smoothing of aggregated data and as such is
less sensitive to random measurement error (Table 2).
Furthermore, assigning risk on a continuous scale for a
particular parasite density avoids the problem of assigning
a binary outcome (clinical episode of malaria or not)
based on a continuous, population-averaged model. Vac-
cine efficacy based on attributable fraction estimates may
facilitate comparison between trials in different epidemi-
ological settings and study populations. A comparison of
the relationship between probability of fever and density
in the vaccinated and the unvaccinated group could give
additional insight into the mode of action of the vaccine.
Conclusion
To obtain accurate results, maximize the ability to com-
pare and distinguish between vaccine candidates, and
avoid scuttling promising candidates, it is essential to val-
idate the choice of endpoint and the sensitivity and specif-
icity of the endpoint. Measurement error has a significant
impact on the quality and reliability of the outcome and
should be considered when developing clinical trial pro-
tocols. The type of endpoint chosen determines the extent
to which measurement error may affect the calculation of
VE, ranging from completely obscuring the true efficacy to
differences of a few percentage points. Calculating VE
using attributable fraction may reduce the error intro-
duced by counting parasites and improve the ability to
compare between vaccine trials.
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